中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2018, Vol. 47 ›› Issue (10): 933-938.doi: 10.12007/j.issn.0258-4646.2018.10.016

• 论著 • 上一篇    下一篇

miR-107与非小细胞肺癌的临床病理特征及预后的关联

赵轲, 张永建, 刘奇, 徐迪, 陈宝钧   

  1. 华中科技大学同济医学院附属武汉中心医院胸外科, 武汉 430014
  • 收稿日期:2017-04-10 出版日期:2018-10-30 发布日期:2018-09-30
  • 通讯作者: 陈宝钧 E-mail:baojunch@126.com
  • 作者简介:赵轲(1978-),男,主治医师,硕士研究生.

Circulating miR-107 Expression Correlates with the Clinicopathological Features and Prognosis of Patients with Non-small Cell Lung Cancer

ZHAO Ke, ZHANG Yongjian, LIU Qi, XU Di, CHEN Baojun   

  1. Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
  • Received:2017-04-10 Online:2018-10-30 Published:2018-09-30

摘要: 目的 评估血浆miR-107表达水平与非小细胞肺癌(NSCLC)患者的临床病理特征及预后的关联。方法 纳入196例NSCLC患者,采集外周血和肿瘤组织样本。抽提总RNA,采用实时PCR法检测miR-107的表达水平。结果 NSCLC患者中miR-107在血浆和肿瘤组织中的表达水平正相关(r=0.456,P < 0.001);血浆miR-107表达水平与淋巴结转移(r=0.168,P=0.018)正相关,肿瘤组织miR-107与病理分化(r=0.304,P < 0.001)、肿瘤大小(r=0.230,P=0.001)、淋巴转移(r=0.446,P < 0.001)以及TNM分期(r=0.294,P < 0.001)正相关;NSCLC患者的5年无病生存期(DFS)和总生存期(OS)分别为13.6%和32.8%;血浆和肿瘤组织中miR-107高表达均与较短的DFS与OS相关;单元Cox风险回归模型显示,血浆和肿瘤组织中miR-107高表达可预测患者较短的DFS和OS,进一步采用多元Cox风险回归模型分析,结果表明,血浆miR-107高表达(P=0.005)仅可独立预测患者的OS,而肿瘤组织中miR-107高表达可独立预测患者的DFS及OS(均P < 0.001)。结论 循环miR-107可作为新颖可靠的生物标记物用于评估NSCLC患者的临床病理特征和预后情况。

关键词: 血浆, miR-107, 非小细胞肺癌, 临床病理特征, 预后

Abstract: Objective To evaluate the association of plasma microRNA-107 (miR-107)expression with the clinicopathological properties and prognosis in non-small cell lung cancer (NSCLC)patients. Methods Plasma and tumor tissue samples were collected from 196 NSCLC patients. Total RNA was extracted and miR-107 expression was evaluated by real-time polymerase chain reaction. Results Expression of miR-107 in plasma was positively associated with expression in tumor tissue (r=0.456,P < 0.001)and with lymph node metastasis (LYM) (r=0.168,P=0.018),but was not correlated with other clinicopathological features. In the tumor tissue samples,miR-107 expression was positively correlated with pathological grade (r=0.304,P < 0.001),tumor size (r=0.230,P=0.001),LYM (r=0.446, P < 0.001),and TNM stage (r=0.294,P < 0.001). The 5-year disease-free survival (DFS)and overall survival (OS)rates were 13.6% and 32.8%,respectively. Kaplan-Meier curves revealed the correlations of the high expression of plasma miR-107 with worse DFS (P=0.002) and OS (P < 0.001)compared to that of low expression. High expression of miR-107 in tissue samples was associated with worse DFS (P < 0.001)and OS (P < 0.001). Univariate Cox proportional hazard regression analysis indicated correlations of high expression of miR-107 in plasma (P=0.003)and tissue (P < 0.001)with worse DFS and OS. Multivariate Cox regression analysis revealed that high expression of miR-107 in plasma (P=0.005)might predict OS for NSCLC,while high expression of miR-107 in tumor tissue is an independent risk factor for shorter DFS and OS (both P < 0.001). Conclusion Circulating miR-107 is a novel and potentially important prognostic biomarker in NSCLC patients.

Key words: circulating, miR-107, non-small cell lung cancer, clinicopathological features, prognosis

中图分类号: 

  • R734.2
[1] FAN H,SHAO ZY,XIAO YY,et al. Incidence and survival of nonsmall cell lung cancer in Shanghai:a population-based cohort study[J]. BMJ Open,2015,5(12):e009419. DOI:10.1136/bmjopen-2015-009419.
[2] TORRE LA,BRAY F,SIEGEL RL,et al. Global cancer statistics, 2012[J]. CA Cancer J Clin,2015,65(2):87-108. DOI:10.3322/caac.21262.
[3] HERBST RS,HEYMACH JV,LIPPMAN SM. Lung cancer[J]. N Engl J Med,2008,359(13):1367-1380. DOI:10.1056/NEJMra0802714.
[4] PARK SJ,MORE S,MURTUZA A,et al. New targets in non-small cell lung cancer[J]. Hematol Oncol Clin North Am,2017,31(1):113-129. DOI:10.1016/j.hoc.2016.08.010.
[5] DONG H,LEI J,DING L,et al. MicroRNA:function,detection,and bioanalysis[J]. Chem Rev,2013,113(8):6207-6233. DOI:10.1021/cr300362f.
[6] AYREMLOU N,MOZDARANI H,MOWLA SJ,et al. Increased levels of serum and tissue miR-107 in human gastric cancer:correlation with tumor hypoxia[J]. Cancer Biomark,2015,15(6):851-860. DOI:10.3233/CBM-150529.
[7] JIANG R,ZHANG C,LIU G,et al. MicroRNA-107 promotes proliferation,migration,and invasion of osteosarcoma cells by targeting tropomyosin 1[J]. Oncol Res,2017,25(8):1409-1419. DOI:10.3727/096504017X14882829077237.
[8] WANG Y,CHEN F,ZHAO M,et al. MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3'UTR[J]. Biochem Biophys Res Commun,2016,480(3):455-460. DOI:10.1016/j.bbrc.2016.10.070.
[9] ZHANG JJ,WANG CY,HUA L,et al. miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2[J]. Int J Clin Exp Pathol,2015,8(5):5168-5174.
[10] WAN JC,MASSIE C,GARCIA-CORBACHO J,et al. Liquid biopsies come of age:towards implementation of circulating tumour DNA[J]. Nat Rev Cancer,2017,17(4):223. DOI:10.1038/nrc.2017.7.
[11] ZHANG Z,ZHANG L,YIN ZY,et al. miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8[J]. Int J Clin Exp Pathol,2014,7(10):7236-7241.
[12] CHEN PS,SU JL,CHA ST,et al. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans[J]. J Clin Invest,2017,127(3):1116. DOI:10.1172/JCI92099.
[13] LI F,LIU B,GAO Y,et al. Upregulation of microRNA-107 induces proliferation in human gastric cancer cells by targeting the transcription factor FOXO1[J]. FEBS Lett,2014,588(4):538-544. DOI:10.1016/j.febslet.2013.12.009.
[14] ZHANG M,WANG X,LI W,et al. miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma(GAC)cells[J]. Biochem Biophys Res Commun, 2015,460(3):806-812. DOI:10.1016/j.bbrc.2015.03.110.
[15] STUCKRATH I,RACK B,JANNI W,et al. Aberrant plasma levels of circulating miR-16,miR-107,miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients[J]. Oncotarget,2015,6(15):13387-13401. DOI:10.18632/oncotarget.3874.
[16] INOUE T,ⅡNUMA H,OGAWA E,et al. Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer[J]. Oncol Rep,2012, 27(6):1759-1764. DOI:10.3892/or.2012.1709.
[1] 徐国帅, 蔡相军, 陈江波, 吕庆, 刘洪涛. AEG-1和CHD5在胃癌中的表达及其临床意义[J]. 中国医科大学学报, 2018, 47(9): 797-802.
[2] 王倩文, 徐振华, 王志静, 苏荣健, 陈学军, 谷艳娇. 葡萄糖调节蛋白78对L858R突变的非小细胞肺癌erlotinib敏感性的影响[J]. 中国医科大学学报, 2018, 47(8): 701-704.
[3] 马艳梅, 常箫匀. 结直肠癌患者围手术期肠内外联合营养支持与预后的关系[J]. 中国医科大学学报, 2018, 47(7): 604-608.
[4] 姜文娟, 刘文静, 李晓曦, 沈雪莉. 1例急性原发性胼胝体变性病例的回顾分析[J]. 中国医科大学学报, 2018, 47(7): 657-659.
[5] 芦婷婷, 王治博. 术前血浆纤维蛋白原和D-二聚体水平与结直肠癌预后的关系[J]. 中国医科大学学报, 2018, 47(6): 513-518.
[6] 武佳科, 田春阳, 何东旭, 宋佳, 于彤彤, 孙志军, 孙兆青. 休克指数对行经皮冠状动脉介入治疗的急性心肌梗死患者长期预后的预测价值[J]. 中国医科大学学报, 2018, 47(6): 522-526.
[7] 刘晓, 王彤, 蒋怡芳, 王媛. 病原学阳性与阴性的医院获得性肺炎患者临床特征及预后比较[J]. 中国医科大学学报, 2018, 47(5): 406-410,414.
[8] 俞达辉, 吴道立, 袁冲, 褚文炎. 癌组织中CD45RO表达水平与肺腺癌患者临床病理特征及生存率的关联分析[J]. 中国医科大学学报, 2018, 47(5): 448-453.
[9] 邵洋, 胡延平, 刘勇. 慢性淋巴细胞白血病患者长链非编码RNA RP5-180C18.1的表达及其预后评价作用[J]. 中国医科大学学报, 2018, 47(4): 341-345.
[10] 张苏宁, 刘宗昂. 小细胞肺癌中DBC1的表达及预后相关性研究[J]. 中国医科大学学报, 2018, 47(3): 222-225.
[11] 王鸾, 蔡雪, 赵敏. 急性百草枯中毒死亡危险因素分析[J]. 中国医科大学学报, 2018, 47(3): 237-239,243.
[12] 李蕙伊, 刘畅, 赵洋子, 曾仁庆, 甘淼, 王涛, 于诗源, 崇巍. 急诊科成人创伤患者院内死亡危险因素分析[J]. 中国医科大学学报, 2018, 47(2): 128-131.
[13] 赵雪峰, 赵美兰, 许广大. TMPRSS4在胃癌中的表达及其临床意义[J]. 中国医科大学学报, 2018, 47(11): 969-974.
[14] 裘敬平, 党军, 蔡峰, 李光. 基于病史、体征、血常规的食管癌预后评分系统的初步构建[J]. 中国医科大学学报, 2018, 47(1): 36-41.
[15] 唐津天 ,王伯庆 ,唐泽天 ,佟庆 ,薛峰 ,徐林 ,易超 ,晏冬. 循环 miR-106a/b 表达水平在肝细胞癌的诊断及预后中的作用[J]. 中国医科大学学报, 2017, 46(9): 830-835.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA